Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo

Annals of Neurology

Volumn 51, Issue 3, 2002, Pages 369-372

  Badrising, Umesh A ^a   Maat Schieman, Marion L C ^a   Ferrari, Michel D ^b   Zwinderman, Aeilko H ^c   Wessels, Judith A M ^d   Breedveld, Ferdinand C ^e   Van Doorn, Pieter A ^f   Van Engelen, Baziel G M ^g   Hoogendijk, Jessica E ^h   Höweler, Chris J ⁱ   De Jager, Aeiko E ^j   Jennekens, Frans G I ^k   Koehler, Peter J ^c   De Visser, Marianne ^a   Viddeleer, Alain ^a   Verschuuren, Jan J ^b   Wintzen, Axel R ^c  

^a Department of Neurology ^*  (Netherlands)

^b Clinical Pharmacology   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ Interuniversitair Steunpunt Neuromusculair Onderzoek   (Netherlands)

^j Sittard Geleen Heerlen   (Netherlands)

^k UNIVERSITY OF AMSTERDAM   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; METHOTREXATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; HUMAN; INCLUSION BODY MYOSITIS; MALE; MUSCLE CONTRACTION; MUSCLE STRENGTH; MUSCLE WEAKNESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; CREATINE KINASE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; MUSCLE WEAKNESS; MYOSITIS, INCLUSION BODY; PLACEBOS; TREATMENT FAILURE;

EID: 0036197698     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10121     Document Type: Article

References (19)

1. Sporadic inclusion-body myositis and its similarities to Alzheimer disease brain. Recent approaches to diagnosis and pathogenesis, and relation to aging
2. Rimmed vacuoles of inclusion body myositis and oculopharyngeal muscular dystrophy contain amyloid precursor protein and lysosomal markers
3. Abnormal accumulation of prion protein mRNA in muscle fibers of patients with sporadic inclusion-body myositis and hereditary inclusion-body myopathy
4. Sporadic inclusion body myositis: Counts of different types of abnormal fibers
5. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM
6. Treatment of inclusion-body myositis with IVIg: A double-blind, placebo-controlled study
7. Inclusion body myositis: Treatment with intravenous immunoglobulin
8. The treatment of inclusion body myositis: A retrospective review and a randomized, prospective trial of immunosuppressive therapy
9. Long-term treatment of destructive rheumatoid arthritis with methotrexate
10. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study
11. Inclusion body myositis
12. Epidemiology of inclusion body myositis in the Netherlands: A nationwide study
13. Functional evaluation; the Barthel index
14. The Rivermead Mobility Index: A further development of the Rivermead Motor Assessment
15. Inclusion body myositis: Clinical, morphological, physiological and laboratory findings in 18 cases
16. High-dose immunoglobulin therapy in sporadic inclusion body myositis: A double-blind, placebo-controlled study